WHO: Intel Agency for Gates Foundation?

Examining the Foundation's prescient Aug. 2019 purchase of BioNTech stock.

Reviewing BioNTech’s Disclosure of Classes of Share Capital for the year ended December 31, 2019, I noticed the following:

On August 30, 2019, BioNTech entered into agreements with the Bill & Melinda Gates Foundation (BMGF). BMGF agreed to purchase 3,038,674 ordinary shares with nominal amount of k€ 3,039 of BioNTech for a total of k€49,864 (k$55,000). These agreements require BioNTech to perform certain research and development activities to advance the development of products for the prevention and treatment of HIV and tuberculosis. In the event of a breach of the underlying conditions, including such research and development activities, BMGF has the right to sell its shares back to BioNTech at the initial share price or fair market value, whichever is higher, subject to certain conditions. BioNTech’s ability to pay dividends is also limited under the terms of these agreements.

Less than two years after the Gates Foundation purchased the stock (pre-IPO) at $18 per share, it peaked on Aug. 6, 2021 at $389. At that price, the Foundation’s $55 million investment was worth $1,182,044,186.00 ($1.182 billion).

On September 18, 2019—just nineteen days after the Gates Foundation took its huge position in BioNTech stock— a report titled A World At Risk was published by the Global Preparedness Monitoring Board, which was founded in 2018 by the World Bank Group and the World Health Organization.

The report’s title page is illustrated with an image of a coronavirus, and its text is an urgent call to action for the world to invest far more in preparedness for a respiratory viral pandemic. As the report states on page 8:

The report mentions nothing about the need to invest in bolstering bio-laboratory safety. It expressly warns about the threat of a lethal respiratory pathogen “accidentally or deliberately released,” but its entire call to action is to invest a fortune to responding to such a pathogen instead of preventing it from being released in the first place.

This was in spite of numerous urgent warnings from Rutgers University biology professor Richard Ebright and others that many of the world’s bio-labs had a history of grave security lapses that were NOT being adequately addressed. In 2017, Professor Ebright expressed particular concern about the new BSL-4 lab that was about to open in Wuhan, China.

We now know that SARS-CoV-2 was officially detected in December of 2019 but probably emerged and started spreading in August or September of 2019—that is, around the same time A World At Risk was published.

The September 18, 2019 date of the report strongly suggests that someone doing bio-surveillance for the WHO in China obtained intelligence that a SARS coronavirus was already circulating.

Given that the Gates Foundation is the WHO’s second largest donor (after Germany, where BioNTech is headquartered) I wonder if this intelligence was passed to someone in the Gates Foundation months before December 31, 2019—the date the WHO claimed it received its first report of cases of pneumonia of unknown etiology in Wuhan.

Does the WHO—with its Country Offices obtaining bio-surveillance reports from the field—serve an an unofficial intelligence agency for the Gates Foundation?

If so, it would enable the Foundation to obtain extremely valuable information about emerging infectious disease pathogens—naturally emergent or accidentally or deliberately released—long before other market players obtain this information.